Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Bridgepoint Education ( BPI) upgraded at Piper from Neutral to Overweight. $31 price target. Valuation appears artificially depressed and regulatory clarity is pending.

Boston Scientific ( BSX - Get Report) upgraded at Goldman to Neutral. Estimates have likely bottomed out. $7 price target.

Chubb ( CB) upgraded at Janney from Neutral to Buy. The property/casualty market is improving.

Career Education ( CECO - Get Report) upgraded at Piper from Underweight to Neutral, Piper Jaffray said. $25 price target. Company has a strong balance sheet and generates healthy cash flow.

Con-way ( CNW) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $45 price target. Estimates also increased, to match the company's new guidance.

Diamond Foods ( DMND) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $85 price target. Estimates also boosted, as the Pringles purchase will add to earnings.

Frontline ( FRO - Get Report) downgraded at Sterne to Neutral. Company could face a more prolonged recovery in the tanker market.

Halliburton ( HAL - Get Report) upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $85 price target. Company is leveraged to a solid oil cycle.

Juniper Networks ( JNPR - Get Report) downgraded at Auriga from Buy to Hold. $40 price target. Switching business could be hurt by competition.

Knight Transportation ( KNX) downgraded at BofA/Merrill to Neutral from Buy. $19 price target. Company is facing slower growth.

Netlogic Microsystems ( NETL) downgraded at Auriga from Buy to Hold. $36 price target. Company is facing challenges in multiple areas.

RSC Holdings ( RRR) upgraded at Goldman to Buy. Company is in the early stages of a pricing upcycle.

Sapient ( SAPE) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $15 price target.

Trius Therapeutics ( TSRX) initiated at BofA/Merrill with a Buy rating and $11 price target. Torezolid offers many potential advantages for MRSA, Bank of America/Merrill Lynch said.

End of report.

This article was written by a staff member of TheStreet.